Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jan 6;9(1):85. doi: 10.3390/jof9010085

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 by the author.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Clinical outcomes of annualized severe asthma exacerbation rate (left panels) and change in lung function (right panels) in a randomized, double-blind, placebo-controlled one-year pivotal trial of dupilumab in adult patients with moderate-severe asthma. Top panel: Results of overall study. Dupilumab reduced asthma exacerbations by 46–48% and improved lung function (*** p < 0.001) in both dosage arms of active treatment compared to placebo. Bottom panel: Post hoc analysis of study subjects with serologic ABPA (IgE > 1000 IU/mL, Af-specific IgE > 0.35 IU/mL, eosinophil count > 500) showing pooled results for actively treated subject arms compared to placebo. Dupilumab treatment reduced exacerbations and improved lung function to an even greater degree than seen in the overall study results. Adapted from references [80,82].

Clinical outcomes of annualized severe asthma exacerbation rate (left panels) and change in lung function (right panels) in a randomized, double-blind, placebo-controlled one-year pivotal trial of dupilumab in adult patients with moderate-severe asthma. Top panel: Results of overall study. Dupilumab reduced asthma exacerbations by 46–48% and improved lung function (*** p < 0.001) in both dosage arms of active treatment compared to placebo. Bottom panel: Post hoc analysis of study subjects with serologic ABPA (IgE > 1000 IU/mL, Af-specific IgE > 0.35 IU/mL, eosinophil count > 500) showing pooled results for actively treated subject arms compared to placebo. Dupilumab treatment reduced exacerbations and improved lung function to an even greater degree than seen in the overall study results. Adapted from references [80,82].